SCHEMBL7215674

SCHEMBL7215674

Cc1ccc(-c2ccc(C=O)c(N)c2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.40
ALDH1A1 P00352 4/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RAB9A P51151 2/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40
PTK2B Q14289 1/20 0.40
TDP1 Q9NUW8 3/20 0.39
CYP3A4 P08684 2/20 0.39
TSHR P16473 1/20 0.39
ERN1 O75460 5/20 0.38
MCL1 Q07820 1/20 0.37
DUSP3 P51452 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31556816 0.88 TDP1 (0.48) ALDH1A1MEN1KMT2AKDM4EPOLB
SCHEMBL27683236 0.87 ERN1 (0.39) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL6257642 0.84 TDP1 (0.52) CYP2A6ALDH1A1SMN1; SMN2RAB9AKDM4E
SCHEMBL12121360 0.82 MAPT (0.52) ALDH1A1MEN1KMT2ARAB9AKDM4E
SCHEMBL27937014 0.80 CYP2A6 (0.46) CYP2A6ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5332809 0.77 TYR (0.50) CYP2A6ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL8035343 0.77 TDP1 (0.53) CYP2A6ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL27770212 0.76 CYP2A6 (0.39) CYP2A6ALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL5953299 0.74 TDP1 (0.70) ALDH1A1SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL5734790 0.74 ALDH1A1 (0.58) ALDH1A1KDM4EHPGDTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6627651-B1 Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-09-30 US disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 EP disclosed